Lymphocyte recovery after fingolimod discontinuation in patients with MS
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective To investigate the dynamics of immune cells recovery after treatment discontinuation of fingolimod in real-life clinical practice, we analyzed the course of lymphocyte reconstitution and its potential influencing factors in patients with multiple sclerosis (MS).
Methods We analyzed leukocyte, lymphocyte, and granulocyte counts of 58 patients at 3, 6, and 12 months after fingolimod cessation and the following parameters as potential risk factors for a prolonged lymphopenia up to 12 months: age; sex; Expanded Disability Status Scale, and disease duration at the time of fingolimod start; type and number of previous immunomodulatory treatments; fingolimod treatment duration; lymphocyte count at baseline before fingolimod, at fingolimod stop, and at the time of therapy switch; time interval between fingolimod cessation and new treatment initiation; type of the follow-up immunomodulatory treatment; and corticosteroid administration after fingolimod cessation.
Results All patients showed a drop of the lymphocyte count under fingolimod with no relevant leukopenia or neutropenia. One year after discontinuation, still 22% of the patients were lymphopenic and 54% of them did not reach 80% of the baseline lymphocyte value. Low lymphocyte counts before fingolimod start, under fingolimod, and at therapy switch, successive treatment with rituximab, and pretreatment with mitoxantrone were significantly associated with a prolonged immune cell recovery.
Conclusions Prolonged lymphopenia after fingolimod cessation exists in a subgroup of patients with MS and should be considered in clinical practice, particularly when changing treatment regimens.
Glossary
- EDSS=
- Expanded Disability Status Scale
Fingolimod, a functional antagonist of sphingosine 1-phosphate receptor, effectively reduces long-term clinical and subclinical disease activity of MS by preventing the egression of lymphocytes from lymph nodes, resulting in a reduced lymphocyte count in the peripheral blood.1,2
Despite its efficacy and good tolerability, fingolimod is discontinued by 29% of patients after 2 years treatment duration.3 Most of these patients require a subsequent disease-modifying treatment; however, the treatment-free period must be defined on an individual basis. Disease reactivation and rebound are potential risks in patients stopping fingolimod4; therefore, a long treatment break should be avoided. On the other hand, a rapid therapy switch without considering lymphocyte recovery could be associated with an increased risk of infections. Hence, knowledge of the lymphocyte recovery time and factors influencing it play a crucial role in the management of patients with MS who stop fingolimod. In clinical studies, lymphocyte count has been described to recover to 80% of baseline value by 3 months2; however, less is known about the duration of lymphopenia in real-life clinical practice. We aimed to analyze the course of lymphocyte recovery and potential influencing factors in the first year after fingolimod discontinuation in patients with MS.
Methods
Data of all patients with MS (n = 58) who stopped fingolimod treatment and participated in the Swiss MS Cohort-Study5 in our center were analyzed retrospectively. Only patients receiving fingolimod for at least 1 month and having available blood tests within 1 year after fingolimod cessation were included. Leukocyte, lymphocyte, and granulocyte counts were analyzed at 3, 6, and 12 months after fingolimod cessation. Lymphopenia was defined as ≤0.9 × 109/L, leukopenia as ≤3.5 × 109/L, and neutropenia as ≤1.3 × 109/L. Lymphopenia was further divided into 3 groups: grade 1 (0.8–0.899 × 109/L), grade 2 (0.5–0.799 × 109/L), and grade 3 (<0.5 × 109/L). The following parameters were analyzed for their relation to prolonged lymphopenia: age, sex, Expanded Disability Status Scale (EDSS), and disease duration of the patients at the time of fingolimod start; type and number of previous immunomodulatory regimens; fingolimod treatment duration; time interval between fingolimod cessation and new treatment initiation (in case of therapy switch); lymphocyte count before fingolimod, at fingolimod stop, and at the start of a subsequent treatment; the type of follow-up immunomodulatory treatment after fingolimod cessation; and corticosteroid administration because of relapses after therapy switch.
The association between potential risk factors and lymphocyte count at 12 months was assessed using a simple linear model. Thereafter, significant predictors were adjusted for other covariates in a multiple univariate model because of the small patient number.
Standard protocol approvals, registrations, and patient consents
All patients signed an informed consent and agreed to an anonymous data analysis. The study was approved by the local ethics committee (ID: 2019-02014).
Data availability
Anonymous data will be shared upon request from any qualified investigator.
Results
Baseline characteristics
Fifty-six patients with relapsing-remitting MS and 2 with primary progressive MS were included (Supplemental figure 1, links.lww.com/NXI/A305). Treatment discontinuation reasons included adverse events (n = 17, 29.3%), disease activity (n = 15, 25.9%), secondary progression (n = 12, 20.7%), pregnancy wish/confirmed pregnancy (n = 8, 13.8%), patient's decision (n = 4, 6.9%), newly diagnosed rheumatologic disease (n = 1, 1.7%), and unknown reason (n = 1, 1.7%). Table 1 summarizes the baseline characteristics of the study population.
Baseline characteristics of all patients and of patients with normalized lymphocytes and prolonged lymphopenia 1 year after discontinuation of fingolimod
Most patients continued with an immunomodulatory treatment after fingolimod stop (figure 1).
From all patients who stopped fingolimod, 13 received no further treatment, 6 restarted fingolimod, whereas the remaining patients were switched at least once to another disease-modifying treatment within the first year (A). Eleven patients remained lymphopenic even 12 months after fingolimod cessation, from whom 8 received rituximab as the follow-up treatment (B). Injectables: interferon beta-1a, interferon beta 1-b, or glatiramer acetate.
Lymphocyte counts after fingolimod discontinuation
Prefingolimod lymphocyte count (median 28 days [0–152] before fingolimod start) was available in 53 patients. Three of these patients had lymphopenia (each with grade 1, grade 2, and grade 3, respectively): 2 of them were on interferon beta-1b treatment, whereas 1 patient had received mitoxantrone until 4 years before sampling. Five patients on natalizumab showed lymphocyte counts above the upper limit of normal (>3.3 × 109/L).
To evaluate the grade of lymphopenia under fingolimod, the last available lymphocyte count before therapy cessation was used. We analyzed lymphocyte, leukocyte, and granulocyte counts at the time point of switching to a follow-up treatment (median 1 day [0–80]), and 3 (median 81 days [28–145]), 6 (median 185 days [112–272]), and 12 months (median 369 days [250–477]) after therapy cessation. Lymphopenia because of an immunomodulatory regimen with expected reduction of lymphocyte count <0.5 × 109/L (fingolimod and alemtuzumab) was not included in the analysis. With these criteria, blood tests of 56 patients at fingolimod stop, 29 at therapy switch, 47 for the 3 months, 46 for the 6 months, and 49 patients for the 12 months time point were analyzed.
Fingolimod resulted in a drop of lymphocyte count by 76% compared with pretreatment; however, no leukopenia or neutropenia was detected. Twelve months after fingolimod stop, lymphocyte counts were normalized in 77.6% of the patients and did not reach 80% of the baseline value in 54% (after excluding those with baseline lymphocyte counts >3.3 × 109/L because of preceding natalizumab) (figure 2, A). One year after fingolimod cessation, 11 patients were still lymphopenic (22%) (figure 2, B). Prolonged lymphopenia was mostly grade 2 (Supplemental figure 2, links.lww.com/NXI/A306).
Mean lymphocyte counts (× 109/L) are represented at baseline (black), fingolimod stop (dark gray), and at 3 (light gray), 6 (dark blue), and 12 months (light blue) after fingolimod discontinuation in the total study population (A) and in the patient group with prolonged lymphopenia (B). Corresponding tables represent mean lymphocyte counts (× 109/L), 95% confidence intervals in [] and patient numbers (n). Red dotted lines represent lower limit of lymphocytes (0.9 × 109/L). Significance level **p < 0.001, ***p < 0.0001.
Main characteristics of patients with prolonged lymphopenia
Table 1 shows the characteristics of the 11 patients with prolonged lymphopenia compared with patients with normalized lymphocyte counts. Lymphocyte count before fingolimod start, at fingolimod stop, pretreatment with mitoxantrone, and a following anti CD-20 depleting therapy were associated with prolonged lymphopenia. The association of rituximab and prolonged lymphopenia persisted when adjusting for covariates (table 2).
Association between prolonged lymphopenia and predefined predictors
Glucocorticoid treatment within 1 year after fingolimod cessation showed no association with prolonged lymphopenia. One patient in the lymphopenic group had sepsis because of an infected toe within 1 year after fingolimod stop without any further infections in this patient group.
Characteristics of patients with subsequent rituximab treatment
Eight of 17 patients (47%) who were switched to rituximab showed prolonged lymphopenia. Those patients who stayed lymphopenic on rituximab had a lower EDSS score at the fingolimod start (median 2.5 vs 4.0), and a lower lymphocyte count at baseline (median 1.3 vs 1.7 × 109/L) and at therapy switch (median 0.62 vs 1.02 × 109/L) compared with those without prolonged lymphopenia under rituximab. All patients pretreated with mitoxantrone belonged to the lymphopenic group.
Discussion
Under standardized conditions of clinical trials, prolonged lymphocyte recovery after fingolimod cessation was considered as an exception.3 However, peripheral lymphocyte reconstitution might be prolonged after therapy withdrawal despite preserved lymph node architecture.6,7 Our real-life analysis shows that lymphocytes recover in most patients without—in average—further increase from the levels attained at 3 months postcessation. However, fingolimod-induced lymphopenia persists in 22% of patients for at least up to 1 year after fingolimod stop. Limitations of our analysis are the low patient number and the lack of a standardized follow-up.
Patients with lower lymphocyte counts before fingolimod, under treatment, and at therapy switch, pretreated with mitoxantrone, and on rituximab follow-up treatment seem to be at a higher risk for prolonged lymphopenia. Because rituximab primarily affects B cells and B cells constitute only a minor percentage of lymphocytes, it is conceivable that a prolonged lymphopenia is at least partly caused by the pretreatment with fingolimod.
The described characteristics may have not shown up in clinical trials because patients were treated for a shorter period, previous mitoxantrone treatment was an exclusion criterion, and the effect of a follow-up treatment was not analyzed. It is therefore of utmost importance to evaluate the safety and pharmacodynamics of fingolimod in the context of the treatment history and the future treatments of the patient.
Study funding
No targeted funding reported.
Disclosure
S. Nagy and J. Kuhle have no disclosures related to the manuscript. T. Derfuss serves on scientific advisory boards for Novartis, Merck, Biogen, Genzyme, GeNeuro, Mitsubishi Tanabe Pharma, Roche, and Celgene; has received funding for travel and/or speaker honoraria from Biogen, Genzyme, Novartis, Merck, and Roche; and received research support from Biogen, Novartis, Roche, the European Union, the Swiss National Science Foundation, and the Swiss MS Society. Go to Neurology.org/NN for full disclosures.
Acknowledgment
The authors acknowledge support for the statistical analysis from Sabine Schädelin, MSc, from the Clinical Trial Unit, University of Basel.
Appendix Authors

Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.
- Received July 10, 2019.
- Accepted in final form July 15, 2020.
- Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
- 1.↵
- Cohen JA,
- Khatri B,
- Barkhof F, et al
- 2.↵
- Francis G,
- Kappos L,
- O'Connor P, et al
- 3.↵
- Duquette P,
- Yeung M,
- Mouallif S,
- Nakhaipour HR,
- Haddad P,
- Schecter R
- 4.↵
- Hatcher SE,
- Waubant E,
- Nourbakhsh B,
- Crabtree-Hartman E,
- Graves JS
- 5.↵
- Disanto G,
- Benkert P,
- Lorscheider J, et al
- 6.↵
- 7.↵
- Ghadiri M,
- Fitz-Gerald L,
- Rezk A, et al
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.